Hong Kong, 10 June 2026 — Duality Biotherapeutics, Inc. (DualityBio) disclosed a series of equity movements in its latest Next Day Disclosure Return, reflecting both employee option exercises and an on-market share repurchase.

From 8–10 June, participants in the company’s Pre-IPO Equity Incentive Plan exercised options for a total of 32,300 ordinary shares. Issue prices ranged from HKD 166.0608 to HKD 178.0741 per share, adding roughly 0.04 % to the pre-event share base.

On 10 June, the company also repurchased 10,000 shares on the Hong Kong Stock Exchange at prices between HKD 165.30 and HKD 169.70, for an aggregate consideration of HKD 1.67 million (average HKD 167.42 per share). The purchase falls under the general mandate approved on 20 June 2025, which authorises buybacks of up to 8.80 million shares; cumulative repurchases now total 272,400 shares, representing 0.31 % of the issued shares at the mandate date. A moratorium on new share issues and treasury-share sales runs until 10 July 2026.

After these transactions, outstanding shares (excluding treasury stock) increased by 22,300 to 90.40 million, while treasury shares rose to 272,400. Total issued shares now stand at 90.67 million.